Schrodinger Quarterly Income Statement
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Schrodinger revenue and earnings
In the quarter ended Jun 30, 2026, Schrodinger generated $58.9 million in revenue, up 7.5% from the same quarter a year earlier. Net income was $6.0 million, for a net margin of 10.1% versus a median of -78.8% in the prior 5 quarters. Gross margin was 55.1% (up from 47.8%) and operating margin -70.6%.
Diluted earnings per share came in at $0.08.
Summary generated from market data by MetaCap's automated system. Methodology
Schrodinger income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.89M | 58.59M | 87.23M | 54.32M | 54.76M | 59.55M | 88.32M | 35.29M | 47.33M | 36.60M | 74.13M | 42.57M |
| Revenue growth (YoY) | +7.54% | -1.62% | -1.23% | +53.94% | +15.69% | +62.72% | +19.14% | -17.10% | +34.51% | -43.51% | +30.40% | +15.11% |
| Cost of Revenue | 26.46M | 29.04M | 29.94M | 26.29M | 28.60M | 28.43M | 24.19M | 17.56M | 16.00M | 17.71M | 16.58M | 18.93M |
| Gross Profit | 32.43M | 29.55M | 57.29M | 28.04M | 26.16M | 31.12M | 64.13M | 17.73M | 31.34M | 18.89M | 57.55M | 23.64M |
| Operating Expenses | 73.98M | 78.34M | 74.45M | 73.99M | 79.06M | 82.01M | 84.84M | 86.15M | 84.06M | 86.32M | 87.17M | 79.83M |
| Research & Development | 41.00M | 43.82M | 41.40M | 42.76M | 43.14M | 45.84M | 49.36M | 50.98M | 50.84M | 50.61M | 51.49M | 46.83M |
| Selling, General & Admin | 32.98M | 34.52M | 33.05M | 31.23M | 35.92M | 36.17M | 35.48M | 35.17M | 33.23M | 35.71M | 35.68M | 33.00M |
| Operating Income | -41.55M | -48.79M | -17.16M | -45.95M | -52.90M | -50.89M | -20.71M | -68.42M | -52.73M | -67.43M | -29.62M | -56.19M |
| Other Income (Expense) | 48.89M | -10.82M | 50.13M | 13.31M | 10.02M | -8.89M | -18.54M | 30.20M | -1.24M | 13.16M | -1.89M | -8.72M |
| Pretax Income | 7.35M | -59.62M | 32.97M | -32.63M | -42.89M | -59.78M | -39.25M | -38.23M | -53.96M | -54.27M | -31.51M | -64.91M |
| Income Tax | 1.37M | 408.00K | 462.00K | 162.00K | 287.00K | 28.00K | 963.00K | -90.00K | 83.00K | 456.00K | -842.00K | -2.89M |
| Net Income | 5.97M | -60.03M | 32.51M | -32.80M | -43.17M | -59.81M | -40.22M | -38.14M | -54.05M | -54.72M | -30.67M | -62.02M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -1363.37% | -142.38% | — | — |
| EPS (Basic) | 0.08 | -0.81 | 0.45 | -0.45 | -0.59 | -0.82 | -0.55 | -0.52 | -0.74 | -0.76 | -0.44 | -0.86 |
| EPS (Diluted) | 0.08 | -0.81 | 0.45 | -0.45 | -0.59 | -0.82 | -0.55 | -0.52 | -0.74 | -0.76 | -0.41 | -0.86 |
| Shares Outstanding (Basic) | 74.71M | 73.99M | — | 73.61M | 73.43M | 73.06M | — | 72.81M | 72.71M | 72.29M | — | 71.92M |
| Shares Outstanding (Diluted) | 75.77M | 73.99M | — | 73.61M | 73.43M | 73.06M | — | 72.81M | 72.71M | 72.29M | — | 71.92M |
| EBITDA | -40.06M | -47.32M | -15.72M | -44.48M | -51.37M | -49.30M | -18.95M | -66.86M | -51.33M | -66.00M | -28.27M | -54.92M |
| Gross Margin | 55.07% | 50.43% | 65.68% | 51.61% | 47.77% | 52.26% | 72.61% | 50.24% | 66.20% | 51.61% | 77.64% | 55.53% |
| Operating Margin | -70.55% | -83.28% | -19.67% | -84.58% | -96.61% | -85.45% | -23.45% | -193.88% | -111.40% | -184.25% | -39.96% | -132.00% |
| Net Margin | 10.15% | -102.46% | 37.27% | -60.37% | -78.84% | -100.43% | -45.54% | -108.06% | -114.18% | -149.53% | -41.38% | -145.70% |
This table shows 12 quarterly periods of Schrodinger's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SDGR's reporting calendar. What is a income statement?